Pharmacy benefits manager Express Scripts is attractively priced given its ability to fend off competitors for years to come.
Readers share which industries they're banking on for the long haul.
PowerShares Buyback Achievers targets firms which have had the financial strength to keep buying shares, but beware of the high price tag.
Near-term challenges abound, but cost advantage should allow the retail giant to defend its turf.
The near term's not so bright, but we still like the long-term picture.
The shift to subscription-based pricing should pay off in the long term.
The firm is on track to meet our full-year estimates, and our $60 per share fair value estimate and wide moat rating are intact.
We don't expect to make any significant changes to our fair value estimate for Altria MO following the release of fourth-quarter and full-year results by the firm. While the company's core tobacco franchises, Philip Morris USA and Philip Morris International, performed well in 2006, Altria's ...
2013 results once again demonstrate the value of Berkshire's diversified portfolio, as solid and consistent performance from the firm's non-insurance operations helped smooth out some of the volatility seen in its insurance businesses.
Morningstar StockInvestor editor Matt Coffina offers some of his new investment ideas following a quarterly rebalancing of the Wide Moat Focus Index.